tradmap

BEAM Beam Therapeutics Inc.

$34.12 +5.00%

Healthcare · Biological Products, (No Diagnostic Substances)

Beam Therapeutics Inc. (BEAM) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $3.5 billion. Shares last traded at $34.12, 6.1% below their 52-week high. Over the past year the stock is up 102.5%. Net profit margin is -57.2%, below the peer median of 6.3%. Revenue grew 120.0% year over year.

Market Cap
$3.5B
Shares Out
102.9M
EPS (TTM)
$-7.69
P/E Ratio
P/S Ratio
25.12
P/B Ratio
3.01
Dividend / Share
Dividend Yield
52-Week High
$36.35
52-Week Low
$15.60
Volume
61,977
Avg Vol (3m)
99,939.857

Performance

1W
+16.01%
1M
+29.64%
3M
+35.53%
6M
+27.46%
YTD
+25.76%
1Y
+102.49%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
61.94
SMA (50)
$30.15
SMA (200)
$26.99
Price vs SMA50
+13.18%
Price vs SMA200
+26.40%
ATR (14)
$2.15

Financials

Revenue
$140M
Net Income
$-80M
Gross Margin
Operating Margin
-274.6%
Net Margin
-57.2%
Return on Equity
-6.9%
Return on Assets
-5.4%
Current Ratio
16.99
Debt / Equity
0.09
Revenue Growth (YoY)
+120.0%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.91 2026-05-07
FY 2025 $-0.81 2026-02-24
Q3 2025 $-3.32 2025-11-04
Q2 2025 $-2.23 2025-08-05
Q1 2026 $-1.23 2026-05-07
FY 2025 $-4.58 2026-02-24

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

BEAM vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
25.12 / 5.21 med
+382% premium
Net margin vs peers
-57.2% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.